Work

Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.185

Authors: Nicholas J. Vogelzang, Jeffrey L. Vacirca, Philip W. Kantoff, Mark C. Scholz, Shaker R. Dakhil, Luke T. Nordquist, Celestia S. Higano, A. Oliver Sartor, Matthew R. Cooperberg, Andrew Sandler, Candice McCoy, James Boyd Whitmore, Robert Claude Tyler, Andrew J. Armstrong

Institutions: Comprehensive Cancer Centers of Nevada, Harvard University, Dana-Farber Cancer Institute, Urology Cancer Center and GU Research Network, University of Washington, Tulane University, University of California, San Francisco, Dendreon (United States), Duke University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591535654

Cites:

Cited by: 1

Related to: 10